Last updated: 11/07/2018 13:23:54
A Comparison of the Efficacy and Safety of Augmentin 875/125 mg po q 12 hours versus Augmentin 500/125 mg po q 8 hours in the Treatment of Lower Respiratory Tract Infections.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Comparison of the Efficacy and Safety of Augmentin 875/125 mg po q 12 hours versus Augmentin 500/125 mg po q 8 hours in the Treatment of Lower Respiratory Tract Infections.
Trial description: A Comparison of the Efficacy and Safety of Augmentin 875/125 mg po q 12 hours versus Augmentin 500/125 mg po q 8 hours in the Treatment of Lower Respiratory Tract Infections.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Amoxicillin/Clavulanate BID vs. A/C TID in the Treatment of Lower Respiratory Tract Infections, Calver, A, MD; Walsh, N, MD; Quinn, P, MD. Orkney, South Africa; Longford, Ireland; Sligo, Ireland; San Francisco, CA; USA. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 9/17/1995
Augmentin BID versus Augmentin TID in the Treatment of Lower Respiratory Tract Infections (LRTI), Calver, A D, MD; Walsh, N, MD; Quinn, P, MD. Orkney, South Africa; Longford, Ireland; Sligo, Ireland; Montreal, QC; Canada. 19th International Congress of Chemotherapy. 7/16/1995
Calver A, Walsh N, Quinn P, Baran C,Lonergan V, Singh K, Orzolek W, etal. Dosing of Amoxicillin/Clavulanate Given Every 12 Hours Is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection. Clinical Infectious Disease 1997; 24:570-4
Medical condition
Infections, Respiratory Tract
Product
amoxicillin/clavulanic acid
Collaborators
Not applicable
Study date(s)
September 1992 to June 1993
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1993-15-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website